Edwards vs. CoreValve
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences files patent suit Feb. 12 against CoreValve in Delaware District court alleging CoreValve's ReValving percutaneous aortic valve replacement system infringes three Edwards' patents related to transcatheter heart valves. Edwards has filed similar litigation in Germany and the U.K. The latest suit is directed at CoreValve devices made in the United States and sold in Europe, where ReValving earned a CE mark in May 2007. Edwards recently launched its Sapien transcatheter aortic replacement heart valve in Europe and has begun the PARTNER pivotal trial of the device in the United States (1"The Gray Sheet" Sept. 10, 2007, In Brief)
You may also be interested in...
Edwards v. CoreValve in U.K.
CoreValve and Edwards Lifesciences each claimed victories Jan. 9 in patent infringement cases involving competing transcatheter valve technology. A U.K. court found the product design for CoreValve's ReValving system for transcatheter aortic valve replacement does not infringe on a patent held by Edwards. But the court also upheld the validity of Edwards' U.K. Andersen patent for transcatheter valve technology, dismissing a CoreValve suit. An Edwards lawsuit against CoreValve in the U.S., citing infringement against the U.S. patent for the same technology, is still pending (1"The Gray Sheet" Feb. 18, 2008, In Brief). The ReValving system is not available in the U.S
Edwards Lifesciences transcatheter heart valve gains European market go-ahead
Edwards will launch its Sapien transcatheter aortic heart valve in Europe in the fourth quarter following CE mark clearance, announced Sept. 5. The device is indicated for patients at high risk for open surgery. While the initial clearance covers use of Sapien with the firm's RetroFlex transfemoral delivery system, Edwards expects expanded approval by year end for use with its Ascendra transapicaldelivery system. The approval reportedly sets the stage for projected Sapien sales of over $20 million in 2008. A U.S. trial also is underway (1"The Gray Sheet" March 26, 2007, p. 10). Competitor CoreValve gained European approval of its ReValving percutaneous aortic valve in May, but has not yet fully commercialized the product (2"The Gray Sheet" May 21, 2007, In Brief). CoreValve also has a transapical system in development...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.